

REMARKS

This Response, filed in reply to the Office Action dated May 30, 2007, is believed to be fully responsive to each point of objection and rejection raised therein. Accordingly, favorable reconsideration on the merits is respectfully requested.

Claims 1-12 are all the claims pending in the application, of which Claims 7-12 are withdrawn from consideration as being directed to nonelected inventions. Claims 1-6 are rejected. Claims 5, 6, 8 and 9 are cancelled. Claims 1-4, 7 and 10-12 are amended, and entry of these amendments is respectfully requested.

Applicants respectfully request rejoinder of the non-elected claims upon allowance of the elected claims.

Claim Rejections - 35 U.S.C. §112

Claims 1-6 are rejected under 35 U.S.C § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention.

The Office Action alleges that the claims are indefinite because recitation of “or the like” within the specification leaves the definition of “substituted” open-ended, including elements which are not actually disclosed. Solely to advance prosecution, Applicants amend the third paragraph on page 7 of the specification. Applicants respectfully submit that this amendment overcomes the rejection.

Further, the Office Action alleges that recitation of “a sulfotransferase inhibitor which comprises the galactosamine derivative according to claim 1” in claims 5 and 6 allows for the inclusion of other elements besides the derivative of claim 1. The Office Action also asserts that

it is unclear whether Claims 5 and 6 are intended to be compound claims or composition claims. This rejection is moot in view of the cancellation of the rejected claims.

Withdrawal of the rejection is therefore respectfully requested.

Claim Rejections - 35 U.S.C. §102

Claims 1, 2, 5 and 6 are rejected under 35 U.S.C 102(b) as allegedly being anticipated by Habuchi *et al.* (*The Journal of Biological Chemistry* 1985, Vol. 260, No. 24, 13102-13108).

Solely to advance prosecution, Applicants hereby amend Claims 1 and 2. Applicants respectfully submit that these amendments overcome the rejection, since the currently presented claims exclude a compound in which R₁ and R₂ are H, R₅ is SO₃⁻, R₃ is an acetyl group, R₄ is a para-nitrophenyl group and X is O, and exclude a compound in which R₁, R₂, and R₅ are each independently SO₃⁻ or H, R₃ is H, an acetyl group or SO₃⁻, R₄ is a benzyl group and X is O. Claims 2, 3 and 4 should be patentable at least by virtue of their dependency from claim 1.

Claims 1-6 are rejected under 35 U.S.C. 102(b) as being anticipated by Dahlgren, *et al.* (WO 97/00879, January 9, 1997).

Applicants respectfully submit that the amendments to claims 1 and 2 render the rejection moot. Claims 2, 3 and 4 should be patentable at least by virtue of their dependency from claim 1.


Withdrawal of the rejection is therefore respectfully requested.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the

Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Sunhee Lee
Registration No. 53,892

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: August 27, 2007